- 1 Low-dose chemotherapy combined with delayed immunotherapy in the 2 neoadjuvant treatment of non-small cell lung cancer and dynamic monitoring of
- 3 the drug response in peripheral blood
- 4 Chaoyang Liang^{1†}, Qi Song^{2†}, Wenhao Zhou^{3†}, Na Li^{3†}, Qi Xiong², Chaohu Pan³,
- 5 Shaohong Zhao⁴, Xiang Yan², Xiaoling Zhang², Yaping Long⁵, Juntang Guo¹, Tao
- 6 Wang¹, Weiwei Shi², Shengjie Sun², Bo Yang¹, Zhouhuan Dong⁶, Haitao Luo^{3*}, Jie
- 7 Li^{6*} , Yi Hu^{2*}, and Bo Yang^{2*}
- 8
- ¹Department of Thoracic Surgery, the First Medical Center, Chinese PLA General
- 10 Hospital, Beijing, China.
- ²Department of Oncology, Chinese PLA General Hospital, Beijing, China.
- ¹² ³Shenzhen Engineering Center for Translational Medicine of Precision Cancer
- 13 Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, China.
- ⁴Department of Radiology, the First Medical Center, Chinese PLA General Hospital,
- 15 Beijing, China.
- ⁵School of Medicine, Nankai University, Tianjin, China.
- ⁶Department of Pathology, the First Medical Center, Chinese PLA General Hospital,
- 18 Beijing, China.
- 19

[†]Chaoyang Liang, Qi Song, Wenhao Zhou, and Na Li contributed equally to this
work.

- 22
- 23 ** Correspondence
- 24 Bo Yang: yangbo@301hospital.com.cn
- 25 Yi Hu: huyi@301hosptial.com.cn
- 26 Jie Li: lijiek812@301hospital.com.cn
- 27 Haitao Luo: luohhaitao@yucebio.com
- 28

29 Abstract

Background: Despite chemo-immunotherapy has been applied to the neoadjuvant treatment of non-small cell lung cancer (NSCLC), the impacts of dosage and the order of medication on treatment efficacy and safety remain largely unexplored. We originally designed an exploratory study to investigate the efficacy and safety of reduced-dose chemotherapy combined with delayed immunotherapy as well as the dynamic changes of circulating tumor DNA (ctDNA) and T cell receptor (TCR) during the therapy.

Methods: Patients with clinical stage IIA to IIIA resectable NSCLC were treated with cycles of reduced-dose platinum-based chemotherapy on day 1 combined with immunotherapy on day 5. The same postoperative modified adjuvant therapy regimen was administered for 2 cycles. Plasma samples at different time-points were collected and performed with T cell receptor (TCR) and circulating tumor DNA (ctDNA) sequencing.

43 **Results:** 38 patients received modified chemo-immunotherapy. The proportion of 44 patients exhibiting complete response and partial response was 5.3% and 68.4%, 45 respectively. The confirmed objective response rate was 73.7%. Radiological 46 downstaging was achieved in 39.5%. Major pathologic response and complete 47 pathologic response were observed in 47.4% and 31.6% of patients, respectively. 48 Only one patient experienced grade 3 adverse event. Further analyses revealed that 49 this modified chemo-immunotherapy led to the expansion of predominant TCR clones 50 and reduction of tumor burden after the first cycle of chemotherapy.

51 **Conclusion:** The promising clinical efficacy and low side effects of modified 52 neoadjuvant chemo-immunotherapy position it as a prospective and innovative 53 strategy for NSCLC.

Funding: This study was funded by the National Natural Science Fund of the
People's Republic of China (NSFC; No.81902912).

56

57 Trial registration: Registration Number: ChiCTR2000033092

2

58

- 59 Keywords: Non-small cell lung cancer, Modified neoadjuvant chemo-immunotherapy,
- 60 Low-dose chemotherapy, Delayed immunotherapy, Treatment efficacy, Side effects,
- 61 Circulating tumor DNA, T cell receptor
- 62

63 Background

64 Approximately 20 to 25% of patients diagnosed with NSCLC are eligible for surgical 65 resection (1), yet 30% to 55% of those who undergo curative surgery will encounter 66 recurrence and ultimately die (2, 3). Despite the improvement in treatment of NSCLC 67 patients, the 5-year survival rates remain relatively low, hovering around 36% (4). 68 Over the past decade, neoadjuvant platinum-based chemotherapy, followed by surgery, 69 has become the standard of care. Nevertheless, only 5 to 6 % improvements have been 70 noted in 5-year recurrence-free survival and overall survival rates compared to 71 surgery alone (5).

72

73 Currently, combination of chemotherapy with immunotherapy has demonstrated 74 superior clinical efficacy and prolonged event-free survival for patients with 75 resectable NSCLC. Trials such as CheckMate 816 (6), SAKK 16/14 (7), and NADIM 76 (8), have showcased the enhanced efficacy and manageable safety of combination 77 therapy compared to monotherapy. However, for most previous clinical trials, 78 cytotoxic drugs with standard doses and anti-PD1 antibody were administrated on the 79 same day (9), which may result in unsatisfactory eradication rates and relatively high 80 incidence of severe treatment-related adverse events (TRAEs). To improve the cure 81 rate and reduce TRAEs, the use of low-dose chemotherapy may represent a feasible 82 alternative, given it favorable tolerability profile without compromising efficacy (10, 83 11). Although various regimens of low-dose chemotherapy have been utilized in 84 cancer therapy (12, 13), the effects of dosage and administration sequence on the 85 efficacy and safety of NSCLC treatment remain controversial. According to our 86 previous research findings, the administration of immunotherapy 3-5 days after

87 chemotherapy significantly reduces lymphocyte damage (14). Therefore, we 88 hypothesize that by coordinating the dosage of chemotherapy and the timing of 89 immunotherapy administration, we can enhance the synergistic effects between the 90 two interventions. Ultimately, this could improve clinical efficacy while reducing 91 toxic side effects.

92

93 To monitor the therapeutic efficacy during the process of chemo-immunotherapy, 94 there is an urgent requirement for reliable indicators. The T cell receptor (TCR) 95 repertoire and the presence of circulating tumor DNA (ctDNA) in blood have been 96 proven to be efficient predictors of therapeutic responses in cancer treatment (15, 16). 97 Chemotherapeutic agents have the capability to induce immunogenic death of tumor 98 cells, reduce tumor burden, and promote the infiltration of CD8 T lymphocyte (17, 99 18). The recognition of tumor antigens by CD8 T lymphocytes relies primarily on the 100 presence of a diverse and polymorphic TCR within an individual (19). Hence, it is 101 imperative to explore the dynamic changes of TCR diversity and tumor burden in 102 ctDNA throughout the course of therapy.

103

104 In this study, we report the results of our pilot clinical trial assessing the efficacy and 105 safety of modified neoadjuvant chemo-immunotherapy in patients with resectable 106 NSCLC. These results indicate that the combination of low-dose chemotherapy 107 followed by delayed immunotherapy could potentially induce tumor cell damage, 108 promote antigen exposure, and support T cell expansion, thereby enhancing 109 therapeutic efficacy and reducing toxic side effects. Monitoring the dynamic changes 110 of TCR repertoire and ctDNA does not only offer insights into the mechanism 111 underlying our therapeutic approach to some extent but also furnishes valuable data 112 for monitoring treatment efficacy.

113

114 Materials and Methods

115 Study design and participants

116 38 Patients with resectable stage IIA to IIIA NSCLC, as per the staging criteria 117 outlined by the American Joint Committee on Cancer, 8th edition, and possessing 118 adequate organ function, along with an Eastern Cooperative Oncology Group 119 performance-status rating of 0 to 1, were included in this study. All patients had not 120 received any prior cancer treatment, exhibited measurable disease according to the 121 Response Evaluation Criteria in Solid Tumors (version 1.1) and had confirmed 122 histological or cytological evidence of the disease. Exclusion criteria included the 123 presence of identified EGFR mutations or ALK translocations; a diagnosis of 124 malignancies beyond NSCLC within 5 years; previous exposure to specific therapies 125 such as anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or medications targeting T cell 126 receptor modulation (e.g., CTLA-4, LAG-3, or TIM-3); a history of allogeneic organ 127 hematopoietic stem cell transplantation (except corneal transplantation); ongoing or 128 repercussions from prior interventions; pregnancy or breastfeeding; and HIV 129 positivity. Moreover, the availability of pre- and post-adjuvant treatment tumor tissues 130 and serial blood samples facilitated comprehensive analyses including whole 131 transcriptome sequencing, TCR sequencing, and ctDNA sequencing.

132

133 Trial design and treatment

134 This study was a single-center, single-arm, pilot clinical trial (Registration Number: 135 ChiCTR2000033092). Eligible patients aged from 45 to 72 received 2 cycles of 136 neoadjuvant therapy of low-dose platinum-based chemotherapy: albumin-bound paclitaxel 180-220 mg/m² plus cisplatin 60 mg/m² for lung squamous 137 cell carcinoma or pemetrexed disodium 500 mg/m² plus cisplatin 60 mg/m² for lung 138 139 adenocarcinoma respectively on day 1 plus sintilimab 200 mg on day 5 of each cycle, 140 followed by radiographic evaluation before undergoing radical surgery. Surgery was 141 conducted within 6 weeks after the completion of neoadjuvant treatment. Then 142 patients would receive 2 cycles of adjuvant therapy with the same regimen.

143

144 Study outcomes

5

145 The primary endpoints include objective response rate (ORR: the proportion of 146 patients with complete response (CR) or partial response (PR) according to response 147 evaluation criteria in solid tumors) and major pathologic response (MPR) (less than 148 10% residual viable tumor cells in the primary tumor and sampled lymph nodes) 149 according to the pathologist review. Secondary endpoint included pathologic complete 150 response (pCR) (0% residual viable tumor cells in the primary tumor and sampled 151 lymph nodes), disease free survival (DFS), treatment-related adverse events (TRAEs), 152 occurrence of surgical complications, and intraoperative and perioperative 153 complications.

154

155 Plasma collection, cell-free DNA extraction, and sequencing

156 Blood samples were collected into cell-free DNA blood streck tubes. Isolated plasma 157 and paired white blood cell (WBC) control were stored at -80 until extraction. 158 Cell-free DNA (cfDNA) and WBC-derived DNA were extracted from 4 mL plasma 159 and WBC using QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) 160 and Mag-Bind® Blood & Tissue DNA HDQ 96 kit (OMEGA) according to the 161 manufacturer's instructions, respectively. DNA extracts were sheared to 100 bp 162 fragments using an S220 focused ultrasonicator (Covaris, Woodbrun, MA, USA). The 163 adaptors (NadPrep®) were attached to the terminal of fragments and followed by 164 PCR (Bio-Rad T100, USA) replication. The libraries were constructed using NadPrep 165 Plasma Cell-Free DNA Dual-Ended Molecular Tag Library Construction Kit (for MGI) 166 (Nanodigmbio). The target customized probes YuceOne Plus (ctDNA) synthesized by 167 IDT were used for hybridization enrichment. Target enrichment was performed with 168 NadPrep Hybrid Capture Reagents (Nanodigmbio). The enriched DNA fragments 169 were sequenced with the MGISEQ platform. The mean depth of coverage was $3445 \times$ 170 for cfDNA and 1419× for matched peripheral blood samples.

171

172 Circulating tumor DNA (ctDNA) analysis

173 SOAPnuke was implemented to cut the adapter and remove low-quality raw reads

174 (20). Genecore was performed for cluster reads by unique molecule index (UMI) and 175 remove the replicated reads derived from PCR (21). Clean reads were aligned against 176 the human reference genome (hg19) with BWA (v0.7.12) (22) and duplicated reads 177 were removed by samtools (v0.1.19) (23). Subsequently, generated BAM files were 178 used for downstream analysis. We compared the ctDNA samples and matched control 179 blood sequencing data to identify the somatic mutations, including single nucleotide 180 variants (SNVs) and small insertions and deletions (Indels) using mutation caller 181 Vardict (v1.7.0) with default parameters (24). Next, the caller was run with dbSNP 182 (version 147), 1000G (phase3_release_v5), CLINVAR (version 151 ClinVar 183 (nih.gov)), and COSMIC (version 81) data for known polymorphic sites. Substitutions 184 and indels would be filtered out according to the following criteria: 1) low variant 185 allelic fractions (VAF < 0.0005), 2) removed any variants with greater than 1 186 supporting read in the matched germline sample, 3) variants present in the above 187 genome database. In addition, the filtered mutations were annotated by snpEff (v4.3) 188 (25) with NCBIrefseq (https://www.ncbi.nlm.nih.gov/refseq/). The maximum VAF is 189 considered as the tumor burden during the therapy.

190

191 Whole transcriptome sequencing

192 The total RNA of tumor samples was isolated using the RNeasy FFPE Kit (Qiagen, 193 GER) according to the manufacturer's instructions. The concentrations of RNA were quantified using Qubit™ RNA HS Assay Kit (ThermoFisher Scientific, USA). RNA 194 195 purity and integrity were checked using the Take3 (BioTek, USA) and the RNA 196 Cartridge kit of the Qseq100 Bio-Fragment Analyzer (Bioptic, CHN), respectively. 197 Then, RNA sequencing (RNA-seq) libraries were constructed using the rRNA 198 depletion module (H/M/R) and NadPrep DNA Library Preparation Module for MGI 199 (MGI, CHN). The libraries were sequenced on the MGISEQ-T7 platform with 100 bp 200 paired-end reads.

201

202 RNA-Seq raw data quality control, gene expression analysis, and immune cell

203 abundance estimation

204 Raw sequencing data (raw reads) from MGISEQ-T7 was processed to filter out 205 low-quality reads. Clean reads from each sample were aligned against the hg19 206 reference by STAR (v2.7.8) (26). The read counts and transcripts per million (TPM) 207 values were calculated based on aligned RNA sequencing reads to reference 208 transcripts downloaded from gencode (v27lift37) database, as implemented in rsem 209 (v1.3.0) (27). Based on the gene expression matrix, R packages xCell (28) and web 210 tool ImmunCellAI (29) were used to estimate the infiltration abundance of immune 211 cells for each sample.

212

213 T cell receptor sequencing and analysis

214 For T cell receptor (TCR) sequencing, total RNA was isolated from peripheral blood 215 mononuclear cells (PBMCs) by RNeasy Plus Mini Kit (Qiagen, USA) according to 216 the manufacturer's instructions. Qubit[™] RNA HS Assay Kit (ThermoFisher Scientific, 217 USA) was applied to determine the final concentration. Then TCR β -chain of CDR3 218 was amplified by Multi-IR Library Prep Kit (iGeneTech, CHN). Sequencing 219 procedures were utilized by the MGISEQ-T7 platform with 100-bp paired-end reads. Fastq reads were trimmed based on their low-quality 3' ends to base. Trimmed 220 221 pair-end reads were integrated according to overlapping alignment with the modified 222 Needleman-Wunsch algorithm. MiXCR (v2.1.10) (30) was performed to identify the 223 CDR3 sequences of V-D-J gene segments with reference sequences from the IMGT 224 (31). VDJtools (v1.2.1) (32) was utilized to assess the immune repertoire sequencing. 225 A frequency-based correction was performed on samples. The diversity of the TCR 226 repertoire was calculated with the Shannon-Wiener index formula $H = -\sum_{i=0}^{n} \rho_i \ln p_i$ represents the frequency of clonotype i for the sample with n 227 228 unique clonotypes. The evenness of the TCR repertoire was calculated with the formula $\frac{H}{\ln(s)}$, where H was Shannon Weiner index and S was the total number of 229 230 species in a sample, across all samples in the dataset. Clonality is defined as a

normalized Shannon index over n unique clones: clonality = $1 - H/\ln(n)$. The D50 index was also performed to evaluate the diversity according to the top 50% of the total TCR clones in the samples. According to clonotype abundance, TCR clonotypes were defined as large clones when their frequency > 0.001. Based on the frequency ranking, the top 20 most frequent TCR clones and large clones are defined as the predominant TCR clones.

237

238 Statistical analysis

All statistical analyses were implemented by R 4.0 software or SPSS 27.0. Medians and inter quartile range (IQRs) were provided for distributions of observation duration and time intervals. Wilcoxon's Rank-Sum test was used to compare across independent groups. Wilcoxon's Signed-Rank test was used for the pairwise comparison samples. All reported *P* values are two-sided, and *P* values less than 0.05 were considered statistically significant.

245

246 Results

247 Overview of the patient cohort

248 From May 2020 to November 2023, 50 patients diagnosed with NSCLC at stage 249 IIA-IIIA were screened for eligibility, of which 38 received two cycles of modified 250 neoadjuvant chemo-immunotherapy (Fig. 1A). Each cycle featured two phases, 251 corresponding to chemotherapy and immunotherapy (Fig. 1B). Following modified 252 neoadjuvant chemo-immunotherapy, 31 patients underwent R0 resection (Figure 1A 253 and Table S1). The postoperative tissues were subjected to pathological evaluation. 254 Samples from a representative patient (P2) who achieved pCR after neoadjuvant 255 treatment exhibited morphological alterations, characterized by extracellular mucin 256 pools and fibrosis (Fig. 1C). Computed tomography scans demonstrated the 257 obliteration of lung lesions following neoadjuvant therapy (Fig. 1D). 74.2% (27/31) 258 participants received the modified adjuvant chemo-immunotherapy (from time-point 259 T4 to T8) (Fig. 1A and B; Table S1). Detailed treatment regimens are provided in

260 Table S2.

261

Most patients were men (78.7%) and had a smoking history (81.6%). The median age of patients was 64 years (range: 37-77). All patients had ECOG performance status of 0 or 1. Baseline patient characteristics are summarized in **Table 1** and detailed in **Table S1**.

266

267 Clinical efficacy and safety

After neoadjuvant therapy, 39.5% (15/38) patients achieved radiological downstaging (Fig. 2A; Table 2). The ratio of patients with CR, PR, and stable disease (SD) was 5.3% (2/38), 68.4% (26/38), and 26.3% (10/38), respectively, yielding an ORR of 73.7% (28/38) (Fig. 2B). 91.3% (21 of 23) were recurrence-free (Fig. 2C). The median interval between the last dose of sintilimab and surgery was 33 days (interquartile ranges (IQRs) 5.55 days) (Table S1). 47.4% (18/38) patients achieved a MPR and 31.6% (12/38) patients achieved a pCR (Fig. 2D).

275

276 For patients receiving adjuvant therapy, the median interval between the surgery and 277 the adjuvant therapy was 32.1 days (IQRs 7.2 days) (Table S1). Up to January 18, 278 2024, the median follow-up was 14.37 months (IQRs 24.22 months) (Table S1). The 279 median OS and DFS are not reached (Fig. 2E). 44.7% (17/38) patients experienced at 280 least one TRAE (Table 3). Grade 3 TRAEs occurred only in one patient. The most 281 common grade 1 or 2 TRAEs were nausea (15.8%). Previously unreported toxic 282 effects were not observed, and there were no instances of discontinuation of modified 283 neoadjuvant chemo-immunotherapy due to toxicity.

284

285 Low-dose chemotherapy combined with delayed immunotherapy has a positive 286 effect on T lymphocytes

To investigate whether dynamic changes in peripheral blood TCR repertoire wereassociated with treatment efficiency during modified chemo-immunotherapy, 49

289 peripheral blood samples were collected from serial time-points and evaluated using 290 TCR sequencing (Fig. 3A). Since the predominant number of TCR clones is an 291 important indicator of immune response and treatment efficacy (15, 33-35), the 292 frequency of the top 20 TCR clones was analyzed at each treatment phase. Significant 293 increase of top 20 TCR clones were observed in phase 1 to 3 (all P < 0.0001; Fig. 3B; 294 Fig. S1). An overall increase of top 20 frequency was observed in the first cycle of 295 neoadjuvant therapy (C1). In contrast, no significant changes were observed during 296 adjuvant therapy (Fig. 3C; Table S3). These results suggested that the peripheral 297 blood-derived top 20 TCR clones were continuously increased not only during 298 low-dose chemotherapy, but also during immunotherapy within neoadjuvant therapy. 299

300 According to clonotype abundance, the TCR clones were divided into 3 clonotypes, 301 including large (frequency > 0.001), median (0.001-0.0001), and small (< 0.0001) 302 clones. A markedly increase of large clones was observed during neoadjuvant therapy 303 (all P < 0.05) (Fig. 3D and E), consistent with the trend of top 20 TCR clones. No 304 significant difference was observed in the diversity, evenness, and clonality of TCR 305 clones across the whole treatment procedure (Fig. 3F; Fig. S2; Table S4). The 306 changes of T lymphocytes in the tumor microenvironment across the neoadjuvant 307 therapy were analyzed based on transcriptomic data. As shown in Figure S3, the 308 CD4+ and CD8+ T lymphocytes tended to increase during neoadjuvant therapy. 309 Collectively, the neoadjuvant treatment had a positive effect on T lymphocytes.

310

311 **Reduced tumor burden in ctDNA was observed during neoadjuvant therapy**

To monitor the dynamic changes of tumor burden in ctDNA during therapy, peripheral blood samples were collected at serial time-points (T0 to T7) and evaluated via ctDNA sequencing. The landscape of genomic alternations was shown in Figure 4A. Among the detected genes, *TP53* (50%) was the most frequently mutated gene, followed by *ARID1A* (11%), *DNMT3A* (11%), and *PIK3CA* (11%) (**Fig. 4A; Table S5**). Throughout the entire treatment, the maximal somatic variant allelic frequency

318 (maxVAF) of ctDNA had a declining trend, especially in PH1 (T0 to T1) with 319 dramatically decreased (P < 0.05) (Fig. 4B; Fig. S4), indicating that low-dose 320 chemotherapy would induce tumor cell death thus reducing tumor burden. Notably, 321 we observed that the changes in TCR and ctDNA exhibited opposite trends during the 322 neoadjuvant therapy (Fig.3B and 3D; Fig. 4B). Taken together, these results suggest 323 that low-dose chemotherapy combined with delayed immunotherapy not only cause 324 the increase of tumor antigens shed into blood but also stimulate the body's immunity 325 to produce more tumor antigen-specific T lymphocytes.

326

327 Discussion

328 In recent clinical trials, the combination of neoadjuvant chemotherapy with 329 immunotherapy by administering them concurrently in patients with resectable 330 NSCLC has brought about longer event-free survival (6, 8, 36). Although 331 chemotherapy promotes tumor cell death and T lymphocyte infiltration (17, 18), it 332 may also have negative effects on T lymphocyte proliferation (37). Consequently, the 333 combination of chemotherapy with immunotherapy has been a topic of controversy. 334 Therefore, the optimal dose, timing of administration, and sequence of therapy need 335 urgent investigation.

336

337 Our previous findings from both in vitro experiments and clinical trials have 338 suggested that administering PD-1/PD-L1 inhibitors at 1-10 days (especially 3-5 days) 339 after chemotherapy in lung cancer patients may be more effective than administering 340 them before or concurrently (14). In this trial, we reported the safety and efficacy of 341 low-dose platinum-based chemotherapy combined with delayed immunotherapy for 342 patients with stage IIA to IIIA resectable NSCLC. After modified neoadjuvant therapy, 343 ORR was achieved in 73.7% (28/38) of patients, which was higher than the report of 344 CheckMate-816 (54%) (6) and comparable to those of NADIM (76%) (8) and 345 LungMate 002 (76%) (38) trials. MPR was achieved in 47.4% (18/38) patients, with 346 31.6% (12/38) achieving pCR. During a median follow-up of 14.37 months, 91.3%

347 (21/23) patients were recurrence-free. These results indicated that modified 348 neoadjuvant chemo-immunotherapy was effective in patients with resectable NSCLC. 349 Only 2.6% (1/38) patients experienced serious TRAEs after receiving modified 350 neoadjuvant treatment, which is lower than the rates reported in CheckMate 816 351 (33.5%), NAMID (30.0%) (8), and LungMate 002 (6.0%) (38) trials. The reduction of 352 chemotherapeutics may contribute to the low incidence of serious TRAEs. 353 Additionally, we did not observe treatment discontinuation due to toxicity. These 354 results provide evidences that low-dose platinum-based chemotherapy combined with 355 delayed immunotherapy as a neoadjuvant therapy is safe and less toxic.

356

357 Previous research has illustrated an association between clinical benefit and TCR 358 repertoire as well as ctDNA level at baseline (39, 40). However, the dynamic changes 359 in the TCR repertoire and ctDNA level during neoadjuvant treatment have been less 360 studied. In our study, we found that the predominant TCR clones were greatly 361 increased after the treatment of chemotherapy from phase 1 to 3, indicating that 362 low-dose platinum-based chemotherapy did not inhibit the proliferation of 363 predominant T cell clones which create a beneficial microenvironment for subsequent 364 immunotherapy. Moreover, ICI treatment significantly increased the number of 365 predominant TCR clones during neoadjuvant therapy, suggesting that immunotherapy 366 has a positive impact on TCR clones, consistent with the study by Forde et al (41). 367 During adjuvant therapy, no significant fluctuation in the predominant TCR clones 368 was observed, probably because the tumor lesions were cleared. Under such 369 circumstances, no tumor antigen was released, thus no tumor antigen-specific T cells 370 were proliferated. Similarly, no significant change was observed in evenness or 371 clonality of TCR. MaxVAF of ctDNA was dramatically dropped during phase 1, 372 which is accordance with previous studies (42-44). Notably, the maxVAF of ctDNA 373 and predominant TCR clones showed opposite trends of change in phase 1. Moreover, 374 the maxVAF of ctDNA was close to 0 during adjuvant therapy stage.

375

13

Our study had several limitations that need to be acknowledged. First, it was a pilot study with a relatively small cohort and lacked a control arm. Therefore, validation of our findings in larger cohorts is necessary. Second, the follow-up period was short, and longer-term results are needed to investigate whether modified therapy provides long-term survival benefits. Finally, innovative techniques should be incorporated to further explore the underlying mechanisms of superior clinical efficacy and reduced TRAEs.

383

In this study, the modified neoadjuvant low-dose platinum-based chemotherapy combined with delayed immunotherapy in patients with resectable NSCLC exhibited promising efficacy and feasibility. The multi-omics analyses provide the dynamic trajectories of the TCR repertoire and tumor burden, which can aim in better understanding the mechanisms of superior efficiency and the feasibility of modified chemo-immunotherapy. In the future, it is possible to conduct large-scale clinical research using this modified chemo-immunotherapy.

391

392 Acknowledgements

393 We would like to thank Innovent Biologics, Inc for providing sintilimab for this study.

394

395 Author's contributions

396 C.Y. Liang: Conceptualization, Formal analysis, Methodology, Writing - original draft. 397 Q. Song: Formal analysis, Methodology, Funding acquisition, Writing - original draft. 398 W.H. Zhou and N. Li: Formal analysis, Methodology, Writing - original draft. C.H. 399 Pan, Q. Xiong B. Yang, and X.L Zhang: Formal analysis. S.H Zhao, W.W. Shi, X. Yan, 400 J.T. Guo, S.J. Sun, Z.H. Dong, and Y.P. Long: Validation, Writing - reviewing & 401 editing. B. Yang, J. Li, Y. Hu, and H.T. Luo: Conceptualization, Investigation, 402 Validation, Verification of underlying data, Supervision, Writing - reviewing & 403 editing.

404

405 Funding

- 406 This study was supported by the National Natural Science Fund of the People's
- 407 Republic of China (NSFC) No.81902912.
- 408

409 Data availability statement

410 All the analysis data can be found in the supplementary tables. The dataset supporting

411 the conclusions of this article is available in the Genome Sequence Archive for

412 Human (GSA-H) repository with accession number (HRA002904) and can be

413 accessed thru the URL (BIG Search - National Genomics Data Center - BIG Search

- 414 (cncb.ac.cn)) after reasonable request.
- 415

416 **Declarations**

417 Ethics approval and consent to participate

418 Ethics committee/IRB of General Hospital of the People's Liberation Army gave

- ethical approval (S2020-144-01) and written informed consent was obtained from all
- 420 participants.
- 421

422 Consent for publication

423 Not applicable.

424

- 425 Competing interests
- 426 The authors declare no conflicts of interest.
- 427

428 **References**

- 429 1. Liang Y, Wakelee HA. Adjuvant chemotherapy of completely resected early stage
- 430 non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2013;2(5):403-10.
- 431 2. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl
- 432 Lung Cancer Res. 2014;3(4):242-9.
- 433 3. Taylor MD, Nagji AS, Bhamidipati CM, Theodosakis N, Kozower BD, Lau CL,

et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann
Thorac Surg. 2012;93(6):1813-20; discussion 20-1.

- 436 4. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE,
 437 et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM
 438 Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for
 439 Lung Cancer. J Thorac Oncol. 2016;11(1):39-51.
- 440 5. Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a
 441 systematic review and meta-analysis of individual participant data.
 442 Lancet.383(9928):1561-71.
- 6. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.
 Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J
 Med. 2022.
- 446 7. Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et
- 447 al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients
- With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase
 II Trial. J Clin Oncol. 2021;39(26):2872-80.
- 8. Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M,
 et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung
 cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. The Lancet
 Oncology. 2020;21(11):1413-22.
- 454 9. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.
 455 Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. The New
 456 England journal of medicine.386(21):1973-85.
- 457 10. Gangopadhyay A, Nath P, Biswas J. Reduced Dose Intensity of Chemotherapy
 458 may not Lead to Inferior Palliation in Locally Advanced Carcinoma of the Gall
 459 Bladder: An Experience from a Regional Cancer Centre in Eastern India. J
 460 Gastrointest Cancer. 2015;46(3):297-300.
- 461 11. Zhang L, Lu S, Cheng Y, Hu Z, Wu YL, Chen Z, et al. Docetaxel maintenance
 462 therapy versus best supportive care after first-line chemotherapy with different dose

docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study,
CTONG-0904): an open-label, randomized, phase III trial. Ann Transl Med.
2021;9(4):338.

12. Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose 466 467 post-transplant cyclophosphamide plus low-dose post-trans plant anti-thymocyte 468 globulin graft-versus-host disease prophylaxis with as 469 fludarabine-busulfan-cytarabine conditioning in haploidentical p eripheral blood stem 470 cell transplantation: A multicentre, randomized c ontrolled clinical trial. Br J 471 Haematol.200(2):210-21.

472 13. Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LO, et al.
473 Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose
474 monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer
475 (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol.
476 2019;4(5):376-88.

477 14. Yao W, Zhao X, Gong Y, Zhang M, Zhang L, Wu Q, et al. Impact of the
478 combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in
479 patients with refractory lung cancer. ESMO Open. 2021;6(2):100094.

480 15. Kidman J, Principe N, Watson M, Lassmann T, Holt RA, Nowak AK, et al.

- 481 Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint
 482 Therapy Responses. Front Immunol. 2020;11:587014.
- 16. Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MPS, et al.
- 484 Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term
- 485 Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res. 2020;26(12):2849-58.
- 486 17. Gaudreau P-O, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, et al.
- 487 Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident M emory T
- 488 Cell, and B Cell Infiltration in Resectable NSCLC. Journal of thoracic oncology :
- 489 official publication of the Internation al Association for the Study of Lung
- 490 Cancer.16(1):127-39.
- 491 18. Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, et al. Cancer-cell-secreted

- 492 CXCL11 promoted CD8⁺ T cells infiltrat ion through docetaxel-induced-release of
- 493 HMGB1 in NSCLC. Journal for immunotherapy of cancer.7(1):42.
- 494 19. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for
- 495 cancer immunotherapy. Science (New York, NY).367(6477):eaax0182.
- 496 20. Chen Y, Chen Y, Shi C, Huang Z, Zhang Y, Li S, et al. SOAPnuke: a MapReduce
- 497 acceleration-supported software for integrated quality control and preprocessing of
- 498 high-throughput sequencing data. (2047-217X (Electronic)).
- 499 21. Chen S, Zhou Y, Chen Y, Huang T, Liao W, Xu Y, et al. Gencore: an efficient tool
- 500 to generate consensus reads for error suppressing and duplicate removing of NGS data.
- 501 BMC Bioinformatics. 2019;20(23):606.
- 502 22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
 503 transform. (1367-4811 (Electronic)).
- 504 23. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve
- 505 years of SAMtools and BCFtools. LID 10.1093/gigascience/giab008 [doi] LID -
- 506 giab008. (2047-217X (Electronic)).
- 507 24. Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al.
- VarDict: a novel and versatile variant caller for next-generation sequ encing in cancerresearch. Nucleic acids research.44(11):e108.
- 510 25. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for
- annotating and predicting the effects of single nucleoti de polymorphisms, SnpEff:
- 512 SNPs in the genome of Drosophila melanogaste r strain w1118; iso-2; iso-3. Fly
- 513 (Austin).6(2):80-92.
- 514 26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR:
- 515 ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
- 516 27. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data
- 517 with or without a reference genome. BMC Bioinformatics. 2011;12:323.
- 518 28. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular
- 519 heterogeneity landscape. Genome Biology. 2017;18(1):220.
- 520 29. Miao Y-R, Zhang Q, Lei Q, Luo M, Xie G-Y, Wang H, et al. ImmuCellAI: A

- 521 Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its
- 522 Application in Cancer Immunotherapy. Adv Sci (Weinh).7(7):1902880.
- 523 30. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva
- 524 EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nature
- 525 Methods. 2015;12(5):380-1.
- 526 31. Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE.
 527 IPD-IMGT/HLA Database. (1362-4962 (Electronic)).
- 528 32. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV,
- 529 Putintseva EV, et al. VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.
- 530 PLoS Comput Biol. 2015;11(11):e1004503.
- 531 33. Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, et al.
- 532 Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic
- 533 Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
- 534 Clin Cancer Res. 2020;26(6):1327-37.
- 535 34. Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z, et al. Peripheral blood T-cell receptor
 536 repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated
 537 with PD-1 inhibitor. Clin Transl Oncol. 2021;23(8):1646-56.
- 538 35. Li Y, Wang J, Wu L, Li X, Zhang X, Zhang G, et al. Diversity of Dominant
- 539 Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins
 540 Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor
 541 Treatment in Advanced Cancers. Front Immunol. 2021;12:649343.
- 542 36. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny
- 543 Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
- 544 The New England journal of medicine.381(21):2020-31.
- 545 37. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks,
- 546 consequences, and new directions for its management. Cancer. 2004;100(2):228-37.
- 547 38. Zhu X, Sun L, Song N, He W, Xie B, Hu J, et al. Safety and effectiveness of
- 548 neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC
- 549 (LungMate 002): an open-label, single-arm, phase 2 trial. BMC Med. 2022;20(1):493.

550 39. van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, Ter

- 551 Elst A, et al. Circulating tumor DNA as a biomarker for monitoring early treatment
- 552 responses of patients with advanced lung adenocarcinoma receiving immune
- 553 checkpoint inhibitors. Mol Oncol. 2021;15(11):2910-22.
- 40. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia Campelo MDR,
- 555 Lazaro M, et al. Pretreatment Tissue TCR Repertoire Evenness Is Associated with
- 556 Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant 557 Chemoimmunotherapy. Clin Cancer Res. 2021;27(21):5878-90.
- 41. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al.
- 559 Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med.560 2018;378(21):1976-86.
- 42. Jiang T, Jiang L, Dong X, Gu K, Pan Y, Shi Q, et al. Utilization of circulating
 cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous
 cell carcinoma. Theranostics.11(1):257-67.
- 43. Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal
 Rubio J, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab
 Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM
 phase II trial). Journal of clinical oncology : official journal of the American Societ y
- 568 of Clinical Oncology.40(25):2924-33.
- 569 44. Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab Plus
- 570 Carboplatin and Paclitaxel as First-Line Treatment f or Advanced Squamous NSCLC
- 571 (CameL-Sq): A Phase 3 Trial. Journal of thoracic oncology : official publication of the

572	Internation al	Association	for the	Study of	Lung	Cancer.1	7(4):54	44-57.
-----	----------------	-------------	---------	----------	------	----------	---------	--------

- 573
- 574
- 575
- 576 577

 Table 1 Baseline clinical characteristics of patients.

Characteristics	Overall (n=38)
-----------------	----------------

Median age (range), years	64 (37-77)				
Sex, n (%)					
Male	28 (78.7%)				
Female	10 (26.3%)				
ECOG performance status, n (%)					
0	8 (21.1%)				
1	30 (78.9%)				
Histological type, n (%)					
Squamous cell carcinoma	21 (55.3%)				
Adenocarcinoma	17 (44.7%)				
TNM stage, n (%)					
IIA	3 (7.9%)				
IIB	12 (31.6%)				
IIIA	23 (60.5%)				
Smoking status, n (%)					
Yes	31 (81.6%)				
No	7 (18.4%)				
PD-L1 TPS, n (%)					
<1%	17 (44.7%)				
1-49%	13 (34.2%)				
\geq 50%	8 (21.1%)				

578 Data are presented as median (range) or n (%). Abbreviations: ECOG, Eastern Cooperative

579 Oncology Group; TNM, tumor-nodes-metastasis; TPS, tumor proportion score.

580

581

Table 2 Response to modified neoadjuvant chemo-immunotherapy

Response to Treatment	Rate (%), Patient No.
Tumor down-staging rate	39.5% (15/38)
R0 resection rate	81.6% (31/38)
ORR	73.7% (28/38)

pCR rate	31.6% (12/38)
MPR rate	47.4% (18/38)

582 Data are presented as n%. ORR, objective response rate; pCR, pathologic complete response;

583 MPR, major pathological response.

584

Table 3 Summary of treatment-related adverse events

Treatment-related adverse	Grade 1 or 2	Grade 3	
events	Grade 1 of 2		
n (%)	16 (42.1%)	1 (2.6%)	
Nausea	6 (15.8%)	0	
Constipation	3 (7.9%)	0	
Decreased appetite	3 (7.9%)	0	
Anemia	2 (5.3%)	0	
Fever	2 (13.0%)	0	
Rash	2 (5.3%)	0	
Decreased neutrophil count	2 (5.3%)	0	
Diarrhea/colitis	1 (2.3%)	0	
Hepatotoxicity	1 (2.6%)	1 (2.6%)	
Hypothyroidism	1 (2.6%)	0	
Adrenal insufficiency	1 (2.6%)	0	
Hyperthyroidism	1 (2.6%)	0	
Maculopapular	0	0	
Hypersensitivity	0	0	
Pneumonitis	0	0	
Hypophysitis	0	0	
thyroiditis	0	0	
Diabetes mellitus	0	0	
Neutropenia	0	0	

586

All data are shown as n (%).

587

588 Figure Legends

589 Fig.1 Overview of study design and representative images.

590 (A) Flow diagram of the study. (B) Trial schema of the study. Patients with NSCLC 591 received modified neoadjuvant chemo-immunotherapy, followed by surgical resection 592 and modified adjuvant chemo-immunotherapy. Tumor tissues were collected at 593 baseline and the surgery phase. Serial blood samples were collected at baseline and 594 each time-point for TCR and ctDNA sequencing. (C) Representative hematoxylin and 595 eosin staining of tumor specimens obtained from patient 2 (P2), who obtained pCR. 596 (D) Representative computed tomographic imaging of lung lesions of P2. NSCLC, 597 non-small cell lung cancer; TCR, T-cell receptor; ctDNA, circulating tumor DNA; 598 pCR, pathologic complete response.

599

600 Fig.2 Clinical efficacy of modified neoadjuvant chemo-immunotherapy.

601 (A) Tumor size changes from baseline based on radiological imaging. (B) Ring 602 diagram showed the rate of overall response according to RECIST criteria (CR, PR, 603 and SD) in patients. (C) Swimmer plot of 31 patients who underwent R0 resection 604 involved in this trial. (D) Barplot showed the number of patients distributed in 605 pathological response (pCR in blue, MPR in green, and non-MPR in red, respectively). 606 (E) DFS curve for patients with modified treatment. CR, complete response; PR, 607 partial response; SD, stable disease; pCR, completed pathological response; MPR, 608 major pathological response; DFS, disease free survival.

609

610 Fig. 3 Dynamic changes in T cell repertoire during therapy.

(A) The schematic of samples collection and analyses performed for each patient. Top boxes represent therapeutic phases, blue for chemotherapy, yellow for immunotherapy, and purple for operation. TCR sequencing is indicated as circle. Square and triangle represents ctDNA and RNA sequencing, respectively. Solid shapes are defined as available data, while open shapes are defined as unavailable

616 data. (B) Comparison of top 20 TCR clones at different therapeutic phases. (C) 617 Comparison of top 20 TCR clones at different therapeutic cycles. For boxplots, each 618 box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal 619 line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \times IQR], 620 and the lower whisker is the max[min(x), Q1 - $1.5 \times IQR$], where x represents the data, 621 Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. (D) 622 Comparison of large TCR clones at different therapeutic phases. (E) Comparison of 623 large TCR clones at different therapeutic cycles. Average and SD are shown. Wilcoxon's Signed-Rank test was used for comparison in B-E (*p < 0.05, **p < 0.01, 624 ***p < 0.001, **** p < 0.0001). (F) Changes in diversity (Shannon index) of TCR 625 clones for each patient. TCR, T-cell receptor; ctDNA, circulating tumor DNA; IQR, 626 627 interquartile range.

628

Fig.4 Characterization of ctDNA and the alteration of tumor burden duringtreatment.

631 (A) Genomic landscape of mutations detected in plasma via ctDNA sequencing. 632 Frequency of mutated genes were shown on the bar of middle and the proportion was 633 shown in numerical form. Counts of mutations for each sample were displayed on top 634 bar. Frequency for each of the six substitutions of the bases spectrum was shown on 635 right. The scale lines below show the proportion of various mutation substitutions. (B) 636 Changes in maxVAF across the entire course of therapy. Wilcoxon's Signed-Rank test 637 was used for comparison. (*p < 0.05). ctDNA, circulating tumor DNA; maxVAF, 638 maximal somatic variant allelic frequency.

639

640 Supplementary materials

Fig. S1 Dynamic change of top 20 TCR clones in the distinct phases.

(A) Changes of top 20 TCR clones of P1, P2, P3, P10, P11, and P12 in T0 to T1 (PH

- 643 1). (**B**) Changes of top 20 TCR clones of P1, P2, P5, P10, P11, and P12 in T1 to T2
- 644 (PH 2). (C) Changes of top 20 TCR clones of P2, P4, P10, P11, and P12 in T2 to T3

645 (PH 3). For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3),

- 646 and the black horizontal line represents the median; the upper whisker is the
- 647 min[max(x), Q3 + 1.5 × IQR], and the lower whisker is the max[min(x), Q1 1.5 ×
- IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile,
- and IQR = Q3 Q1. Wilcoxon's Signed-Rank test was used for comparison (*p < 1
- 650 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). TCR, T-cell receptor; IQR,
- 651 interquartile range.
- 652

653 Fig. S2 Characterization of temporal dynamics of the T cell repertoire in the

- 654 longitudinal blood.
- (A) Changes of the D50 index among patients. (B) Changes of Pielou index (evenness)
- among patients. (C) Changes of clonality index among patients.
- 657

658 Fig. S3 Infiltration of CD4+ and CD8+ T lymphocytes after modified

659 neoadjuvant therapy.

660 (A) Relative proportion of lymphocytes was assessed by ImmunCellAI. (B) Relative 661 proportion of lymphocytes was assessed by xCell. For boxplots, each box indicates 662 the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents 663 the median; the upper whisker is the min[max(x), $Q3 + 1.5 \times IQR$], and the lower 664 whisker is the max[min(x), Q1 - $1.5 \times IQR$], where x represents the data, Q3 is the 665 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. Wilcoxon's 666 Signed-Rank test was used for comparison. Tcm, central memory T cells; Tem, Effector memory T cells; IQR, interquartile range. 667


668


Fig. S4 Change in maxVAF across different phases. For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + $1.5 \times IQR$], and the lower whisker is the max[min(x), Q1 - $1.5 \times IQR$], where x represents the data, Q3 is


- 673 the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 Q1. Wilcoxon's
- 674 Signed-Rank test was used for comparison. IQR, interquartile range.

675


- 676 Table S1. Clinical characteristics of patients
- 677 Table S2. List of treatment regimens
- Table S3. List of top 20 TCR clones frequency across the whole modified therapy
- Table S4. TCR characteristics across the whole modified therapy
- 680 Table S5. Annotation of ctDNA somatic mutations










P2_pre




P2_post









B







P1 P3 P5 P7 P9

